← Eichor
Condition: Hemoglobinopathy Disorder Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hemoglobinopathy Disorder

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Phase N/A · 6 location(s) · Genetix Biotherapeutics Inc. · NCT06271512Effect of EMDR for Reduction of Pain Interference in Children With Sickle Cell Disease
NA · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT07001631A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
NA · 1 location(s) · University of Florida · NCT04484272Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
NA · 1 location(s) · Children's National Research Institute · NCT05099874Stroke Prevention in Nigeria 2 Trial
Phase 4 · 2 location(s) · Vanderbilt University Medical Center · NCT06526117The HOPE Biobank Resource (BMT CTN 2402 HOPE)
Phase N/A · 6 location(s) · Medical College of Wisconsin · NCT07227155Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia M
NA · 1 location(s) · Rawan Mohammed Khairy Mostafa Elsawy · NCT07112703Ultrasound Acute Chest Syndrome Sickle Cell Disease
NA · 1 location(s) · Indiana University · NCT06880679AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Phase 2 · 1 location(s) · University of California, Davis · NCT06016634A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Phase 1 · 3 location(s) · St. Jude Children's Research Hospital · NCT06442761Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease
NA · 1 location(s) · Boston Children's Hospital · NCT06555939Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
EARLY_Phase 1 · 1 location(s) · The 923rd Hospital of Joint Logistics Support Force of Peopl · NCT06107400Long-term Follow-up Study of BRL-101 for TDT
Phase N/A · 7 location(s) · Bioray Laboratories · NCT06298630Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06147414A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Phase 3 · 105 location(s) · Novo Nordisk A/S · NCT06609226Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT03279094Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT07175051Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
Phase 2 · 1 location(s) · St. Jude Children's Research Hospital · NCT05583721Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
NA · 5 location(s) · University of Pittsburgh · NCT04109820Blood Sampling for Research Related to Sickle Cell Disease
Phase N/A · 1 location(s) · National Institute of Diabetes and Digestive and Kidney Dise · NCT00542230FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Phase N/A · 1 location(s) · xCures · NCT06539169Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis
NA · 2 location(s) · Imam Abdulrahman Bin Faisal University · NCT07188766Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
Phase 1/Phase 2 · 6 location(s) · Kamau Therapeutics · NCT04819841Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)
Phase N/A · 1 location(s) · University Hospitals Cleveland Medical Center · NCT02824471Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Phase 2 · 5 location(s) · CSL Behring · NCT07224360A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharma
Phase 2 · 36 location(s) · Bristol-Myers Squibb · NCT05664737Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
NA · 14 location(s) · University of Pittsburgh · NCT06374238A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Phase 3 · 174 location(s) · Novo Nordisk A/S · NCT06612268
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.